Effect of Candesartan on cause-specific Mortality in heart failure patients. The Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program

Patients with heart failure are at increased risk of sudden death and death attributed to progressive pump failure. We assessed the effect of candesartan on cause-specific mortality in patients enrolled in the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) pr...

Full description

Saved in:
Bibliographic Details
Published in:Circulation (New York, N.Y.) N.Y.), 2004-10, Vol.110 (15), p.2180-2183
Main Authors: SOLOMON, Scott D, DUOLAO WANG, POCOCK, Stuart, PFEFFER, Marc A, FINN, Peter, SKALI, Hicham, ZORNOFF, Leonardo, MCMURRAY, John J. V, SWEDBERG, Karl, YUSUF, Salim, GRANGER, Christopher B, MICHELSON, Eric L
Format: Article
Language:English
Subjects:
Aged
Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
Angiotensin II Type 1 Receptor Blockers - therapeutic use
Benzimidazoles - therapeutic use
Biological and medical sciences
Blood and lymphatic vessels
Canada - epidemiology
Cardiac and Cardiovascular Systems
Cardiac/epidemiology/prevention & control
Cardiology. Vascular system
Cardiovascular Diseases - mortality
Cardiovascular Diseases - prevention & control
Cardiovascular Diseases/mortality/prevention & control
Cardiovascular system
Cause of Death
Congestive/drug therapy/mortality
Death
Death, Sudden, Cardiac - epidemiology
Death, Sudden, Cardiac - prevention & control
Disease Progression
Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous
Emergency and intensive care: renal failure. Dialysis management
Female
Great Britain/epidemiology
Heart Failure
Heart Failure - drug therapy
Heart Failure - mortality
Humans
Intensive care medicine
Kardiologi
Left/mortality/prevention & control
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Proportional Hazards Models
Single-Blind Method
Sudden
Sweden - epidemiology
Tetrazoles - therapeutic use
United Kingdom - epidemiology
United States - epidemiology
Vasodilator agents. Cerebral vasodilators
Ventricular Dysfunction
Ventricular Dysfunction, Left - mortality
Ventricular Dysfunction, Left - prevention & control
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Patients with heart failure are at increased risk of sudden death and death attributed to progressive pump failure. We assessed the effect of candesartan on cause-specific mortality in patients enrolled in the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. The CHARM program consisted of 3 component trials that enrolled patients with symptomatic heart failure: CHARM-Alternative (n=2028; LVEF
ISSN:0009-7322
1524-4539
1524-4539
DOI:10.1161/01.CIR.0000144474.65922.AA